Alligator discontinued independent drug development in July 2026. The company’s main focus is its financial interest in HLX22, an anti-HER2 antibody in global Phase 3 development by Shanghai Henlius Biotech, Inc. Alligator does not fund further development of its other assets and is seeking to out-license or divest them.
Alligator is open to licensing or divestment discussions for mitazalimab, its antibody technologies and other remaining assets. The terms and completion of any transaction cannot be guaranteed.
Through its subsidiary Atlas Therapeutics AB, Alligator holds a financial interest in HLX22, an anti-HER2 antibody that originated from a discovery collaboration with AbClon, Inc. Shanghai Henlius Biotech, Inc. develops, funds and will commercialise HLX22, which is in global Phase 3 development in first-line HER2-positive gastric and gastroesophageal junction cancer. Alligator is entitled to 35% of AbClon’s revenues from Henlius, including milestones and royalties, equivalent to an effective royalty of up to 1.75% of HLX22 net sales. Alligator incurs no development costs for this programme.
Parties interested in licensing or acquiring Alligator’s remaining assets or antibody technologies can contact bd@alligatorbioscience.com. Investor enquiries should go to ir@alligatorbioscience.com.